Dirk Kersten

Director Dirk Kersten sold 263,962 shares in 3 transactions for $5,464,611.43 via pre-arranged 10b5-1 plan

Dirk Kersten executed 3 separate sales totaling 263,962 shares ($5.5M) on June 22–23, 2026 at an average blended price of $20.70, reducing his holdings by 6.4%. The sales occurred via a pre-arranged 10b5-1 trading plan, making them scheduled rather than discretionary transactions. At the current price of $20.33, the stock trades -18.7% from its 52-week high of $25.00, though it has risen +17.0% over the past 30 days. Notably, Kersten's cross-ticker track record shows an average 90-day return of -39.7% following his prior 20 sells across all tickers, while his 5 prior trades at DYN alone show consistent 30-day declines ranging from -12.5% to -18.1%. Against this backdrop of consistent post-sale price deterioration, the company remains unprofitable with a net income of $-120,854,000.00 for its most recent fiscal year, adding context to the directional pressure on the stock following insider sales.

Dirk Kersten (Director) sold 84,355 shares at DYN for $1,695,689.49 under 10b5-1 plan; stock up 20.2% in 30 days.

Director Dirk Kersten executed 2 separate sales totaling 84,355 shares for $1,695,689.49 at a blended average price of $20.10, reducing his holding from 4,196,573 shares to 4,112,218 shares (a -2.0% net change). The sales were executed under a 10b5-1 trading plan, meaning they are scheduled and not discretionary. Notably, Kersten's cross-ticker track record shows 20 prior sells with an average 90-day return of -39.7%, while his same-ticker history at DYN (5 prior trades) shows consistent negative 30-day returns ranging from -12.5% to -18.1%. The company reported net income of $-120,854,000.00 for its most recent full fiscal year, reflecting unprofitable operations despite the current market cap of $2,980,751,217.69. Current price is $20.87, positioned at -16.5% from the 52-week high of $25.00.

Director Kersten Dirk sells 337,248 shares for $6,815,190.03; stock down 20.9% from 52-week high; company unprofitable.

Director Kersten Dirk executed 2 separate sales totaling 337,248 shares for $6,815,190.03, reducing holdings by 7.4% (from 4,544,773 to 4,207,525 shares). The sales at a blended average price of $20.21 occurred on 2026-04-17 and 2026-04-20, a period when DYN stock closed at $19.21 current price, down 20.9% from its 52-week high of $24.29. Dyne Therapeutics reported a net loss of $108,041,000.00 for its most recent full fiscal year. His cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 100.00%, but at DYN specifically, 0 of 0 prior measurable 90-day outcomes were well-timed, offering no historical pattern of successful exit timing at this ticker.

Director Kersten Dirk sold 99,613 shares (99.6K) across 3 transactions for $2,027,157.84 ($2.0M) at DYN on 2026-04-15/16.

Kersten Dirk executed three separate sales totaling 99,613 shares for $2.0M, reducing his stake by 2.1% from 4.64M to 4.54M shares. The director sold at an average price of $20.35, compared to the current price of $20.41—a narrow margin. The company is unprofitable with net income of $-108.0M, and the stock is down 16.0% from its 52-week high of $24.29, though it has rallied 11.6% over 30 days and 22.2% over 90 days. Across his cross-ticker track record, this insider's prior sells have posted a 100.00% well-timed rate with an average 90-day return of -48.4%, but at this same ticker (DYN), prior measurable outcomes show mixed results: three sales posted modest returns (ranging from -4.3% to +6.3% at the 30-day mark), and no prior 90-day outcome at DYN has yet been classified as well-timed. The filing itself provides no public FLAG indicating a 10b5-1 plan or other scheduled structure, so timing is a property of this discretionary sale.

Director Kersten Dirk sold 129.7K shares of DYN at $19.52 on 2026-03-11; stock now down to $17.92, -26.2% from 52-week high.

Kersten Dirk (Director) sold 129,672 shares at $19.52, reducing holdings from 4.77M to 4.64M shares (-2.7%). The sale occurred while the stock was trading 30% above its current price of $17.92, and the stock has since declined 26.2% from its 52-week high of $24.29. Dirk's cross-ticker track record shows a 100.00% well-timed rate across 20 prior sells with an average 90-day return of -46.4%, indicating a pattern of selling before significant declines. At DYN specifically, his most recent measurable trade (2024-12-09) delivered a -57.5% 90-day return, demonstrating prior accuracy at this ticker. The company is unprofitable with negative full-year net income of $-108,041,000, providing fundamental context for insider disposition activity.

Director Kersten Dirk sold 688,788 shares for $13,149,313.71 across 4 transactions; holds 4,774,058 shares post-sale.

Kersten Dirk, a Director at Dyne Therapeutics, conducted four separate sales on 2026-03-09 and 2026-03-10, totaling 688,788 shares (688.8K shares) for $13,149,313.71 ($13.1M) at a blended average price of $19.09. This represents a -12.6% reduction in his shareholding, from 5,462,846 to 4,774,058 shares. His prior sales at DYN have shown a 100% well-timed rate at the 90-day mark, with four consecutive prior sells returning -21.0%, -15.6%, -14.8%, and -15.8% in the 30-day periods following those transactions—all negative, indicating the stock declined after his sales. The company is unprofitable with a net loss of $-108,041,000.00 over its most recent full fiscal year, and the stock is currently -17.7% from its 52-week high of $24.29 despite a +17.7% 30-day rally from lower levels. The concentration of four sales within two consecutive trading days, combined with his historical pattern of well-timed exits at this ticker and the company's material losses, may signal heightened attention from the market on capital allocation and insider positioning during a period of elevated volatility.

Director Kersten Dirk sold 136,112 shares ($4.0M) in 2 tranches at $29.30 avg; stock now $28.33, -39.8% from high.

Kersten Dirk (Director) sold 101,675 shares at $29.34 on 2024-12-06 and 34,437 shares at $29.18 on 2024-12-09, totaling $3,988,016.16 at an average price of $29.30. The director retains 5,400,545 shares post-transaction. The current price of $28.33 represents a -39.8% decline from the 52-week high of $47.04, and the stock is down 13.1% over the past 90 days. Dyne Therapeutics is unprofitable, with a net loss of $97,125,000 over its most recent full fiscal year. Across the insider's open-market history, his prior sells averaged -12.1% 30-day returns and -31.6% 90-day returns with a 100.00% well-timed rate, though his recent trades at this ticker (5 prior sells in December 2024) have outcomes not yet measurable.

Director Kersten Dirk sells 138,845 shares ($4.1M) at DYN over two days; stock down 37.3% from 52-week high, company unprofitable.

Kersten Dirk, a Director at Dyne Therapeutics, executed 2 separate sales totaling 138,845 shares for $4,079,360.51 on 2024-12-04 and 2024-12-05 at a blended average price of $29.38. The stock is currently trading at $29.50, down 37.3% from its 52-week high of $47.04 and down 10.7% over the past 90 days. Dirk's cross-ticker track record shows a 100.00% well-timed sell rate across 20 prior open-market sales, with average 90-day returns of -32.0%, suggesting a pattern of selling ahead of declines. However, at DYN specifically, his prior trade executed on 2024-10-17 returned -19.3% over 30 days, and none of his 5 prior DYN trades have yet produced a measurable well-timed 90-day outcome. The company reported a net loss of $97,125,000 in its most recent full fiscal year, indicating ongoing operational challenges despite a $3.0B market cap. The timing of this director-level sale amid significant year-to-date underperformance and negative earnings warrants attention to whether this reflects updated views on near-term prospects.

Director Kersten Dirk sold 110,933 shares for $3.3M across 3 transactions on DYN; stock down 37.4% from 52-week high, company unprofitable.

Kersten Dirk completed 3 separate sales totaling 110,933 shares for $3,273,008.14 at an average price of $29.50, reducing his stake by 1.9%. The company reported a net loss of $97,125,000.00 over its most recent full fiscal year, and the stock is trading 37.4% below its 52-week high of $47.04. While Dirk retains a substantial position of 5.68M shares post-transaction, his recent selling activity at DYN mirrors a consistent pattern: his prior 5 trades at this ticker (all sells occurring between October and early December 2024) have each been followed by negative 30-day returns ranging from -17.9% to -19.7%. His cross-ticker track record shows a 100% well-timed rate on 20 prior sells with an average 90-day return of -32.2%, indicating a demonstrated ability to exit before declines. The timing of this sale—executed near current price levels while the company remains unprofitable—warrants attention to whether the insider perceives elevated downside risk or is responding to operating challenges not yet reflected in broader market sentiment.

Director Kersten Dirk sold 36,684 shares at blended $35.29 for $1.3M, reducing holdings by 29.7%

Kersten Dirk, a Director at Dyne Therapeutics, executed 2 separate sales on 2024-10-16 and 2024-10-17, totaling 36,684 shares for $1,294,437.06 at a blended average price of $35.29. This represents a significant reduction in his DYN holdings—from 123,323 shares pre-transaction to 86,639 shares post-transaction, a -29.7% decline. The sales occurred as Dyne remains unprofitable with a net loss of $65,102,000 for its most recent fiscal year, and the current share price of $35.24 is -25.1% below the 52-week high of $47.04. Additionally, Dirk has executed 5 prior sales at DYN within the same period (2024-09-27 through 2024-10-02), suggesting a pattern of incremental liquidation rather than isolated activity. Investors should note the combination of substantial share reduction, the company's ongoing losses, and proximity to 52-week lows alongside this director's recent elevated selling activity at the ticker.